Drugs used, not listed here:

• Azathioprine and ciclosporin: see section 8.2.1 Immunosuppressive agents
• Mercaptopurine: see section 8.4.7 Nucleoside analogues
  
• Methotrexate: see section 8.4.3 Antifolates
• Adalimumab, Golimumab, Infliximab, Tofacitinib, and Ustekinumab: see section 10.1.3 Drugs used in rheumatic diseases and gout

Etrasimod

• Tablets 2mg

Notes

1. NICE TA956: Etrasimod (Velsipity) is recommended, within its marketing authorisation, as an option for moderately to severely active ulcerative colitis in people aged 16 years and over (March 2024) when:
   1. conventional or biological treatments cannot be tolerated or
   2. the condition has not responded well enough, or lost response to treatment, and
   3. only if the company provides it according to the commercial arrangement.
2. If people with the condition and their clinicians consider etrasimod to be 1 of a range of suitable treatments, after discussing the advantages and disadvantages of all the options, use the least expensive. Take account of administration costs, dosage, price per dose and commercial arrangements.

Mirikizumab

• Solution for infusion vials 300mg/15ml
• Solution for injection pre-filled syringes 100mg/1ml

Notes

1. NICE TA925: Mirikizumab (Omvoh) is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or lost response to treatment (October 2023), only if:
   1. a tumour necrosis factor (TNF)-alpha inhibitor has not worked (that is the condition has not responded well enough or has lost response to treatment or
   2. a TNF-alpha inhibitor cannot be tolerated or is not suitable, and
   3. the company provides it according to the commercial arrangement.

Vedolizumab

• Powder for concentrate for solution for infusion 300mg vial
• Solution for injection pre-filled pens 108mg/0.68ml
• Solution for injection pre-filled syringes 108mg/0.68ml

Notes

1. NICE TA342: Vedolizumab (Entyvio) is recommended, within its marketing authorisation, for treating moderately to severely active ulcerative colitis in adults only if the company provides vedolizumab with the discount agreed in the patient access scheme (June 2015)
2. NICE TA352: Vedolizumab (Entyvio) is recommended as an option for treating moderately to severely active Crohn's disease (August 2015) only if:
   1. a tumour necrosis factor‑alpha inhibitor has failed (that is, the disease has responded inadequately or has lost response to treatment) or
   2. a tumour necrosis factor‑alpha inhibitor cannot be tolerated or is contraindicated
   3. Vedolizumab is recommended only if the company provides it with the discount agreed in the patient access scheme

Darvadstrocel

• NICE TA556: Darvadstrocel (Alofisel) is not recommended for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn's disease (January 2019)